Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / CTRV - ContraVir And CRV431 In NASH: An Update

CTRV - ContraVir And CRV431 In NASH: An Update

ContraVir Pharmaceuticals Inc.

Market Assessment

ContraVir Pharmaceuticals (CTRV) is a small-cap ($3.44M) clinical-stage biopharma developing innovative therapeutics for chronic liver diseases, hepatocellular carcinoma ((HCC)), viral liver diseases (HBV, HCV and HDV) and NASH, with high unmet medical needs. Its drug pipeline initially comprised TXL (formerly CMX157) and CRV431. On April 2019, Contravir terminated the 2014 license agreement with Chimerix (NASDAQ:CMRX) for the development and commercialization of CMX157 in viral infections including HBV.

Presently, CRV431 is its lead investigative drug candidate in clinical development for the treatment of chronic HBV infection and possibly NASH, the

Read more ...
Stock Information
Company Name: ContraVir Pharmaceuticals Inc.
Stock Symbol: CTRV
Market: NASDAQ
Website: contravir.com
Menu
CTRV CTRV Quote CTRV Short CTRV News CTRV Articles CTRV Message Board
Get CTRV Alerts

News, Short Squeeze, Breakout and More Instantly...